IPP Bureau
Serum Life Sciences invests US $ 10 million in GreenLight Biosciences
By IPP Bureau - November 24, 2021
GreenLight Biosciences is a Boston-based biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible
Ipca Laboratories acquires 26 % stake in Lyka Labs, makes open offer
By IPP Bureau - November 24, 2021
For the six months ended September 30, 2021, Lyka had reported revenues of Rs 109.87 crore
Fortis Escorts Faridabad introduces Cryo technique to treat lung cancer
By IPP Bureau - November 24, 2021
Cryo-technology helps in early diagnosis and palliative care in later stages of cancer
Vital Strategies India appoints L. M. Singh as MD, India and Global Head, Partnerships and Innovative Finance
By IPP Bureau - November 24, 2021
In his new role as Managing Director India and Global Head, Partnerships and Innovative Finance, Singh will oversee the financial, human, and operational functions of the India office
Asian Development Bank to loan US $ 300 mn to improve India’s primary healthcare
By IPP Bureau - November 24, 2021
The programme will be implemented across 13 states and benefit 256 min
Indian pharma CEOs bet big on innovation to achieve US $130 bn
By IPP Bureau - November 23, 2021
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
AstraZeneca opens Discovery Centre in Cambridge
By IPP Bureau - November 23, 2021
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
Obseva announces U.S. FDA acceptance of new drug application for linzagolix
By IPP Bureau - November 23, 2021
Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
Boehringer Ingelheim gets CDSCO nod for Jardiance
By IPP Bureau - November 23, 2021
Jardiance is the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death in people with type-II diabetes and established cardiovascular disease
U.S. FDA approves Alembic’s Formoterol Fumarate inhalation solution
By IPP Bureau - November 23, 2021
The ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
Zydus Cadila submits NDA to Drug Controller General of India for Chronic Kidney Disease
By IPP Bureau - November 23, 2021
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Alembic receives tentative U.S. FDA approval for Dabigatran Etexilate capsules
By IPP Bureau - November 23, 2021
Dabigatran Etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE)
Cognota Healthcare partners with Dr Jahangir Alam in his digital foray
By IPP Bureau - November 23, 2021
The platform is a collaborative video solution that enables doctors and medical staff to deliver seamless health care experiences to patients through this digital interface
Philips integrates MedChat’s AI to optimise automated patient communication
By IPP Bureau - November 23, 2021
Hospitals and outpatient clinics can also digitally navigate patients from the time an order is placed, to when it is scheduled and completed through follow-up
CStone and Jiangsu Hengrui sign exclusive licensing agreement for cancer drugs in China
By IPP Bureau - November 22, 2021
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
